« Return to News | Clinical Intelligence

The CenterWatch Monthly, February 2012

Friday, February 3, 2012 12:01 PM

Anticipating the rise of virtual drug development

With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have shown greater interest in buying assets from virtual companies. Benefits of the virtual model include less overhead and faster…

 

Closing investigative site operations a complex process

In light of the shrinking investigative site landscape reported and detailed in our January issue, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into insights into the challenges of exiting the business and how to better manage the process. The site profiles, which each took a different path to closing shop, detail the numerous logistics involved, from ensuring patient safety and considering their employees’ futures to…

 

Eye On Shire

Shire is a rapidly growing, global specialty biopharmaceutical company aiming “to enable people with life-altering conditions to lead better lives.” While based in the U.K. and U.S., it also directly markets its products in over 50 countries. Shire’s stated goal is to have half of its sales originate from beyond the U.S. and European…

 

 To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.